Healthcare -
Medical - Instruments & Supplies - NASDAQ - US
$ 92.51
0.0108 %
$ 5.46 B
Market Cap
45.57
P/E
1. INTRINSIC VALUE
Balance Sheet
Merit Medical Systems, Inc.
| Current Assets | 924 M |
| Cash & Short-Term Investments | 377 M |
| Receivables | 209 M |
| Other Current Assets | 338 M |
| Non-Current Assets | 1.46 B |
| Long-Term Investments | 22.8 M |
| PP&E | 452 M |
| Other Non-Current Assets | 981 M |
| Current Liabilities | 216 M |
| Accounts Payable | 68.5 M |
| Short-Term Debt | 10.3 M |
| Other Current Liabilities | 138 M |
| Non-Current Liabilities | 823 M |
| Long-Term Debt | 800 M |
| Other Non-Current Liabilities | 23.1 M |
EFFICIENCY
Earnings Waterfall
Merit Medical Systems, Inc.
| Revenue | 1.36 B |
| Cost Of Revenue | 713 M |
| Gross Profit | 643 M |
| Operating Expenses | 461 M |
| Operating Income | 156 M |
| Other Expenses | 35.3 M |
| Net Income | 120 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Merit Medical Systems, Inc.
| Net Income | 120 M |
| Depreciation & Amortization | 115 M |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 28.5 M |
| Change in Working Capital | -36.9 M |
| Others | -11.9 M |
| Free Cash Flow | 221 M |
Wall Street Analysts Price Targets
Merit Medical Systems, Inc.
Wall Street analysts predict an average 1-year price target for MMSI of $103 , with forecasts ranging from
a
low of
$85 to a high of $125 .
MMSI Lowest Price Target
Wall Street Target
85 USD
-8.12%
MMSI Average Price Target
Wall Street Target
103 USD
11.02%
MMSI Highest Price Target
Wall Street Target
125 USD
35.12%
4. DIVIDEND
ANALYSIS
MMSI does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Merit Medical Systems, Inc.
Sold
0-3 MONTHS
13.9 M USD 6
3-6 MONTHS
5.21 M USD 3
6-9 MONTHS
0 USD 0
9-12 MONTHS
1.68 M USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Here's Why You Should Retain Merit Medical Stock in Your Portfolio Now
Merit Medical's strong product portfolio raises optimism about the stock.
zacks.com
- 2 weeks ago
Updated ASGE Clinical Practice Guideline Includes TIF 2.0 and cTIF for Management of GERD
Endoscopic anti-reflux therapy recognized as evidence-based approach to providing relief of GERD symptoms. Endoscopic anti-reflux therapy recognized as evidence-based approach to providing relief of GERD symptoms.
globenewswire.com
- 2 weeks ago
Merit Medical Stock May Rise as WRAPSODY CIE Shows Strong Results
MMSI unveils 12-month efficacy data for WRAPSODY CIE, highlighting its advanced technology in vascular access maintenance and potential to improve patient outcomes.
zacks.com
- 3 weeks ago
Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)
SOUTH JORDAN, Utah, March 25, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced that the six-month results from the randomized arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) trial are scheduled for publication in the April issue of Kidney International . Twelve-month results from the randomized arm of the WAVE trial are scheduled for presentation at the Society of Interventional Radiology's 50th Annual Scientific Meeting in Nashville, TN. The podium presentation is scheduled for March 30, 2025, during the late-breaking trials session.
globenewswire.com
- 3 weeks ago
Merit Medical Rings Nasdaq Opening Bell to Celebrate 35-Year Partnership
SOUTH JORDAN, Utah, March 18, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced that Chairman and Chief Executive Officer, Fred Lampropoulos, will visit the Nasdaq MarketSite in Times Square to ring the opening bell on Wednesday, March 19, 2025. The ceremony begins at 9:15 A.M. (EDT) and the bell ringing takes place at 9:30 A.M.
globenewswire.com
- 4 weeks ago
Merit Medical: A Success Story That Keeps Getting Better
Merit Medical continues to outperform, with the share price supported by on-target financial results, incremental M&A, and positive clinical data. The company's Wrapsody stent graft showed almost best-case clinical efficacy, positioning it to capture significant market share in dialysis graft occlusion procedures. Recent acquisitions, including EsophyX Z+ and Cook Medical's lead management portfolio, enhance Merit's product portfolio and offer longer-term synergies.
seekingalpha.com
- 1 month ago
MMSI Announces Commencement of Patient Enrollment in PREEMIE Study
Merit Medical aims to improve care for vulnerable premature infants by evaluating the safety and efficacy of the Bloom Micro Occluder System for treating PDA in the specified patient pool.
zacks.com
- 1 month ago
First Patient Enrolled in Merit Medical's PREEMIE Study
Multicenter, prospective study designed to evaluate safety and efficacy of Bloom™ Micro Occluder System for treatment of patent ductus arteriosus in premature infants Multicenter, prospective study designed to evaluate safety and efficacy of Bloom™ Micro Occluder System for treatment of patent ductus arteriosus in premature infants
globenewswire.com
- 1 month ago
Merit Medical Systems, Inc. (MMSI) Q4 2024 Earnings Call Transcript
Merit Medical Systems, Inc. (MMSI) Q4 2024 Earnings Call Transcript
seekingalpha.com
- 1 month ago
Compared to Estimates, Merit Medical (MMSI) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Merit Medical (MMSI) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
zacks.com
- 1 month ago
Merit Medical (MMSI) Beats Q4 Earnings and Revenue Estimates
Merit Medical (MMSI) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $0.81 per share a year ago.
zacks.com
- 1 month ago
Merit Medical Reports Fourth Quarter and Full Year 2024 Results and Issues Fiscal Year 2025 Guidance
Fourth Quarter Highlights† Reported revenue of $355.2 million, up 9.4% Constant currency revenue* and constant currency revenue, organic* up 10.1% and up 6.1%, respectively GAAP operating margin of 10.3%, compared to 10.4% in prior year period Non-GAAP operating margin* of 19.6%, compared to 16.6% in prior year period GAAP EPS $0.46, down 2.6%, Non-GAAP EPS* $0.93, up 25.8%, and Free cash flow* generation of $65.3 million, up 18.4% Fiscal Year 2024 Highlights† Reported revenue of $1.357 billion, up 7.9% Constant currency revenue* and constant currency revenue, organic* up 8.5% and up 6.0%, respectively GAAP operating margin of 11.5 %, compared to 9.9% in prior year Non-GAAP operating margin* of 19.0%, compared to 17.2% in prior year GAAP EPS $2.03, up 25.3%, Non-GAAP EPS* $3.46, up 21.3%, and Free cash flow* generation of $185.7 million, up 67.5% Fourth Quarter Business Developments Completed the acquisition of lead management portfolio of medical devices and certain related assets from Cook Medical Holdings, LLC Announced FDA premarket approval of the Wrapsody® Cell-Impermeable Endoprosthesis device, which is intended to extend long-term vessel patency in dialysis patients Substantially completed integration of the production, distribution and sale of the EsophyX® Z+ device previously acquired from Endogastric Solutions, Inc. Fiscal Year 2025 Guidance Revenue of $1.470 billion to $1.490 billion, up 8% - 10% year-over-year Non-GAAP EPS of $3.58 to $3.70, up 4% - 7% year-over-year † Comparisons noted in the bullet points are calculated for the current quarter compared with the fourth quarter of 2023 or for the current year compared with fiscal year 2023, as applicable, unless otherwise specified. Amounts in this release are rounded while percentages are calculated from the underlying amounts.
globenewswire.com
- 1 month ago
8. Profile
Summary
Merit Medical Systems, Inc. MMSI
COUNTRY
US
INDUSTRY
Medical - Instruments & Supplies
MARKET CAP
$ 5.46 B
Dividend Yield
0.00%
Description
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures, primarily in cardiology, radiology, oncology, critical care, and endoscopy. The company operates in two segments, Cardiovascular and Endoscopy. It provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. The company also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coated tubes and wires; and sensor components for microelectromechanical systems. In addition, it provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate strictures; gastroenterology products; and kits and accessories for endoscopy and bronchoscopy procedures. The company sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. Merit Medical Systems, Inc. was incorporated in 1987 and is headquartered in South Jordan, Utah.
Contact
1600 West Merit Parkway, South Jordan, UT, 84095
https://www.merit.com
IPO
Date
May 14, 1990
Employees
7400
Officers
Mr. Fred P. Lampropoulos
Founder, Chief Executive Officer, President & Chairman
Mr. Jason Treft
Chief Information Officer
Sarah Comstock
Vice President of Global Communications
Mark Butler
Executive Vice President of Merit Medical EMEA
Clay Creamer
Executive Vice President of Manufacturing Finance & Strategy
Alisha Jerauld
Sustainability Council Chair and Vice President of Environment, Social & Governance
Mr. Brian G. Lloyd J.D.
Chief Legal Officer & Corporate Secretary
Ricardo Alvarez
Managing Director of Operation Merit Medical Tijuana
JoAnne Alkire
Executive Vice President of Global Marketing & Strategy
Mr. Neil W. Peterson
Chief Operating Officer